CycloLab at BIO Digital
As the readers of Cyclodextrin News have been already informed, 2020 BIO International Convention will be a digital event to
Category: Pharma applications
UK grants early access for Gilead’s remdesivir in Covid-19
The government of the U.K. is granting the country’s equivalent to an emergency use authorization to remdesivir, the antiviral drug
Current knowledge about the antivirals remdesivir (GS-5734) and GS-441524 as therapeutic options for coronaviruses
Amirian and Levy have recently collected the knowledge on remdesivir and its nucleoside analog [1]. This overview can be interesting
4th International Biotechnology Congress 2020
The 4th International Biotechnology Congress (IBC-2020) will be held during Nov. 11-13, 2020 in Dubai, UAE. Keynote speakers: Dr. Sergei
First copies of Gilead’s SBECD-enabled remdesivir to start selling in Bangladesh
According to Hindustan Times, Bangladesh’s Beximco Pharmaceuticals Ltd. has become the world’s first company to start selling the generic version
Oculis Top-Line data from Phase 2 clinical trial for OCS-01 treating inflammation and pain after cataract surgery
Oculis, the Icelandic-Swiss clinical stage boipharmaceutical company recently reported new clinical data at the Americal Society of Cataract and Refractive
Cholesterol and COVID19 lethality in elderly
A new study published on the preprint server bioRxiv* in May 2020 suggests that the strikingly increased mortality in COVID-19 patients who
Cyclo Therapeutics reports international patent application for treating Alzheimer’s
Cyclo Therapeutics reported the publication of an international patent application for the treatment of Alzheimer’s disease with HPBCD.
Coronavirus and COVID-19: The latest news and views from the scientific community about the new coronavirus and Covid-19
Coronavirus is a family of viruses that cause respiratory infections.The new coronavirus agent was discovered on 12/31/19 after cases registered
Voluntary Licensing Agreements for Remdesivir
Gilead has signed non-exclusive voluntary licensing agreements with five generic pharmaceutical manufacturers based in India and Pakistan to further expand